プレシジョン治療を現実のものに。

Immuno-Oncology & 免疫療法

お問い合わせ

Access over 50 different syngeneic tumor models, from both solid and disseminated origins, as well as access to commercially generated humanized mouse models or client-generated models

Draw on over 1000 immuno-oncology clinical study experience in the last 10 years

Partner with an oncology contract research organization provider who has served nearly 20,000 immuno-oncology patients in the last five years

Explore Immuno-Oncology and Immunotherapy Capabilities

Immuno-oncology has become a significant opportunity for oncology drug discovery and development. The ability to harness each person's unique immune system in a meaningful way to dampen the deadly effects of tumor cells has created the explosion of precision medicine. Integrate your flow cytometry, efficacy models, imaging, biomarker and companion diagnostics to quickly advance to the next milestone-because patients can't wait.

Discovery immunotherapy

特定の腫瘍モデルの開発に関わる免疫エフェクター細胞と個別の治療法における抗腫瘍反応の媒介に関わる免疫エフェクター細胞を有意義に評価することが重要です。 For many of our models, we have growth curves available, and we continue to build our database with treatment response to agents of interest like anti-CTLA-4, anti-PDL-1 and anti-PD-1 antibodies.

In addition to testing immune-modulating agents themselves or testing other agents in combination with immune-modulators, it is important to consider the impact of radiation therapy, which is being integrated into and increasingly investigated in combination with these immuno-oncology protocols. 放射線療法の未照射部位への遠達効果と免疫調整効果を示すデータに加え、直接組み合わせた抗腫瘍効果を示すデータは概念実証を提供し、前臨床において広く使われ、臨床的に関連性のあるモダリティに関するより詳細な研究を促進しています。

Clinical immuno-oncology

プレシジョンメディシンで進歩を遂げるには、試験を迅速に行い、適切な個人に対して適切な治療を行えるよう的を絞った新たな方法が必要となってきます。 At Labcorp, we have proven experience in immuno-oncology studies, including over 100 protocols in the past five years, performed in 58 countries at more than 2,860 sites with over 19,750 patients.

Our commitment to immuno-oncology is also evident through our support of more than 70% of all FDA-approved companion diagnostic products.極めて重要な最近のフェーズ III 登録治験の一環として、当社のセントラルラボは、新規に FDA の承認を受けた OPDIVO® (nivolumab) の診断検査の前哨となった PD-L1 発現の試験ができた唯一のプロバイダー でした。さらに、コーヴァンスによる最上級のコンパニオン診断機能は、免疫治療である Keytruda®(ペンブロリズマブ)とその PD-L1 コンパニオン診断に加え、TagrissoTM(オシメルチニブ)および EGFR 変異原性試験をも支援しました。

お問い合わせはこちら

お問い合わせ